Bioequivalence Study of DOXIL®/CAELYX®

• Research type

  Research Study

• Full title

  A Pivotal Bioequivalence Study of DOXIL®/CAELYX® Manufactured at a New Site in Subjects with Advanced or Refractory Solid Malignancies including Subjects with Ovarian Cancer

• IRAS ID

  128525

• Contact name

  Rebecca Kristeleit

• Contact email

  r.kristeleit@ucl.ac.uk

• Sponsor organisation

  Janssen-Cilag International N.V

• Eudract number

  2013-000376-15

• Clinicaltrials.gov Identifier

  NCT01815294

• REC name

  North East - Newcastle & North Tyneside 2 Research Ethics Committee

• REC reference

  13/NE/0118

• Date of REC Opinion

  17 May 2013

• REC opinion

  Further Information Favourable Opinion